IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CASULA, MANUELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 23.199
AS - Asia 15.907
NA - Nord America 11.252
SA - Sud America 3.981
AF - Africa 1.013
OC - Oceania 787
Continente sconosciuto - Info sul continente non disponibili 61
Totale 56.200
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.797
CN - Cina 5.971
IT - Italia 3.946
DE - Germania 3.536
ES - Italia 2.859
GB - Regno Unito 2.681
BR - Brasile 1.684
IN - India 1.596
MX - Messico 1.496
FR - Francia 1.446
JP - Giappone 1.341
SG - Singapore 1.050
HK - Hong Kong 840
CO - Colombia 799
CH - Svizzera 793
SE - Svezia 767
TR - Turchia 740
NL - Olanda 737
KR - Corea 699
AU - Australia 660
CA - Canada 645
AT - Austria 644
RU - Federazione Russa 610
PL - Polonia 604
PT - Portogallo 603
ID - Indonesia 598
GR - Grecia 541
TW - Taiwan 541
VN - Vietnam 506
AR - Argentina 477
IE - Irlanda 472
TH - Thailandia 442
DK - Danimarca 423
BE - Belgio 419
PE - Perù 344
FI - Finlandia 338
EG - Egitto 317
CL - Cile 286
RO - Romania 257
EC - Ecuador 240
MY - Malesia 221
IL - Israele 187
NO - Norvegia 187
SA - Arabia Saudita 187
ZA - Sudafrica 184
CZ - Repubblica Ceca 175
IR - Iran 156
PH - Filippine 148
HR - Croazia 147
SI - Slovenia 130
AE - Emirati Arabi Uniti 120
NZ - Nuova Zelanda 120
RS - Serbia 120
SK - Slovacchia (Repubblica Slovacca) 118
UA - Ucraina 117
BG - Bulgaria 109
HU - Ungheria 104
TN - Tunisia 88
CR - Costa Rica 85
PK - Pakistan 80
LT - Lituania 75
DZ - Algeria 73
MA - Marocco 67
VE - Venezuela 67
BA - Bosnia-Erzegovina 63
LB - Libano 63
NG - Nigeria 57
JO - Giordania 49
CY - Cipro 46
DO - Repubblica Dominicana 43
IQ - Iraq 43
EE - Estonia 41
UY - Uruguay 38
QA - Qatar 37
ET - Etiopia 36
GT - Guatemala 32
EU - Europa 31
KE - Kenya 30
KW - Kuwait 29
BD - Bangladesh 28
KZ - Kazakistan 28
MO - Macao, regione amministrativa speciale della Cina 26
PA - Panama 26
AP - ???statistics.table.value.countryCode.AP??? 25
BO - Bolivia 25
HN - Honduras 24
BY - Bielorussia 21
CI - Costa d'Avorio 21
LV - Lettonia 21
PY - Paraguay 21
SV - El Salvador 20
CU - Cuba 19
MT - Malta 17
PR - Porto Rico 17
GH - Ghana 16
IS - Islanda 16
NP - Nepal 16
OM - Oman 15
PS - Palestinian Territory 15
RE - Reunion 15
Totale 55.880
Salva come PNG Salva come JPEG
Città #
Southend 817
Beijing 725
Milan 706
Singapore 628
Shanghai 554
Madrid 485
Tokyo 439
Frankfurt am Main 435
Hong Kong 378
Barcelona 373
Vienna 373
Guangzhou 353
Dublin 345
Rome 342
Bogotá 341
Redwood City 308
Paris 282
Taipei 278
Bormujos 273
Athens 270
New York 269
Istanbul 260
London 257
Ashburn 246
Berlin 235
Lima 234
Mumbai 234
Nanjing 231
Bangkok 229
São Paulo 228
Fairfield 222
Munich 217
Bengaluru 208
Hanover 205
Chicago 204
Los Angeles 203
Chandler 202
Sydney 200
Hanoi 195
Buenos Aires 192
Jakarta 191
Mexico City 191
Zurich 187
Seattle 186
Stockholm 181
Ho Chi Minh City 177
Warsaw 173
Duncan 163
Houston 163
Helsinki 161
Melbourne 160
Santiago 150
Amsterdam 148
Wilmington 146
Wuhan 146
Central 145
Chennai 143
Moscow 133
Brussels 130
Chengdu 129
Hangzhou 129
Medellín 129
Seoul 128
Copenhagen 126
Council Bluffs 125
Hyderabad 123
Cairo 118
Menlo Park 117
Hamburg 116
Kuala Lumpur 116
Naples 116
Tianjin 116
Lisbon 115
Princeton 115
Woodbridge 114
Valencia 112
Cambridge 110
Delhi 109
Bologna 102
Changsha 102
Guadalajara 102
Toronto 102
Ann Arbor 101
Atlanta 101
Ankara 100
Florence 97
Shenyang 96
Rio de Janeiro 95
Turin 90
Breda 89
Quito 86
Shenzhen 86
Guayaquil 85
Jinan 82
Osaka 82
Düsseldorf 81
Riyadh 80
Porto 79
Zagreb 79
Manchester 78
Totale 20.508
Salva come PNG Salva come JPEG
Nome #
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk 29.271
2019 ESC/EAS guidelines for the management of dyslipidaemias : Lipid modification to reduce cardiovascular risk 10.179
Statin use and risk of dementia or Alzheimer's disease : a systematic review and meta-analysis of observational studies 4.728
Statin use and risk of new-onset diabetes : A meta-analysis of observational studies 3.289
Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study 798
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study 717
Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN) 412
Use of proton pump inhibitors and risk of ischemic events in the general population 406
Sex-differences in factors and outcomes associated with adherence to statin therapy in primary care: need for customisation strategies 359
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study 314
Incretin-based drugs and risk of acute pancreatitis: A nested-case control study within a healthcare database 285
Association between the cumulative exposure to bisphosphonates and hospitalization for atherosclerotic cardiovascular events: A population-based study 256
Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting : the PROSISA Study 215
Prevalence of the prescription of potentially interacting drugs 194
Lower Rate of Cardiovascular Complications in Patients on Bolus Insulin Analogues : a Retrospective Population-Based Cohort Study 187
Reply to: "Statins probably do not cause cataracts" 165
Detection of familial hypercholesterolemia in patients from a general practice database 155
Global epidemiology of dyslipidaemias 154
Multilevel Models to Estimate Carotid Intima-Media Thickness Curves for Individual Cardiovascular Risk Evaluation 146
Blood pressure and antihypertensive therapy according to the global cardiovascular risk level in Italy : the CHECK Study 129
Cardiovascular events with PCSK9 inhibitors : an updated meta-analysis of randomised controlled trials 126
Geographical Variation in Medication Prescriptions: A Multiregional Drug-Utilization Study 126
Achilles tendon ultrasonography in familial hypercholesterolemia: A sub-study of the LIpid transPort disorders Italian GEnetic Network (LIPIGEN) 125
Epidemiology of cardiovascular risk factors in two population-based studies 117
Risk Factors Distribution and Cardiovascular Disease Prevalence in a Representative Sample of Italian Population: The CHECK Study 110
Reduction of cardio-metabolic risk and body weight through a multiphasic very-low calorie ketogenic diet program in women with overweight/obesity: A study in a real-world setting 109
Prevalence and relationship between metabolic syndrome and risk of cardiovascular disease: Evidence from two population-based studies 108
Corrigendum to “Incretin-based drugs and risk of acute pancreatitis: A nested-case control study within a healthcare database” [Diabetes Res. Clin. Pract. (2015) 108(2) (243–249)] (S0168822715001138)(10.1016/j.diabres.2015.02.013) 104
HDL in atherosclerotic cardiovascular disease : In search of a role 104
Pentraxin 3 (PTX3) plasma levels and carotid intima media thickness progression in the general population 103
Lipid Lowering and Incidence of Cataract, a Role for Fibrates 102
Statins and the risk of diabetes : evidence from a large population-based cohort study 101
Adherence to lipid-lowering treatment : the patient perspective 100
Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage, and baseline cardiovascular risk matter? An updated meta-analysis of randomized controlled trials 100
Adherence to Mediterranean Diet: A Population-Based Longitudinal Cohort Study 97
Tools to investigate and avoid drug-hypersensitivity in drug development 97
Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, placebo controlled trials 92
Are generic and brand-name statins clinically equivalent? Evidence from a real data-base 90
Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) andtriglyceride-rich lipoprotein metabolism: Facts and gaps 89
Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features 87
Global perspective of familial hypercholesterolaemia : a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) 87
How many patients need statin treatment in a low-cardiovascular-risk country? Low-density lipoprotein-cholesterol target and distance from target distribution in an Italian cohort 86
Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia 86
How registers could enhance knowledge and characterization of genetic dyslipidaemias : The experience of the LIPIGEN in Italy and of other networks for familial hypercholesterolemia 86
Evaluation of Factors Associated With Appropriate Drug Prescription and Effectiveness of Informative and Educational Interventions-The EDU.RE.DRUG Project 85
C-reactive protein distribution and correlation with traditional cardiovascular risk factors in the Italian population 84
Assessment and potential determinants of compliance and persistence to antiosteoporosis therapy in Italy 84
Nutraceuticals for dyslipidaemia and glucometabolic diseases : what the guidelines tell us (and do not tell, yet) 83
A simple informative intervention in primary care increases statin adherence 82
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events 81
Reaching LDL-c targets in high-risk patients requires high-efficacy cholesterol-lowering drugs in more than 50% of cases. The results of the CHECK study 79
Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study 76
Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease : The POSTER study 75
Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations 72
Longevity-associated BPIFB4 gene counteracts the inflammatory signaling. 70
Statin use and risk of cataract : a nested case-control study within a healthcare database 70
Potentially Inappropriate Prescribing among Elderly Outpatients: Evaluation of Temporal Trends 2012–2018 in Piedmont, Italy 70
A pragmatic controlled trial to improve the appropriate prescription of drugs in adult outpatients: Design and rationale of the EDU.RE.DRUG study 70
Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease 64
Approaches to Deprescribing Proton Pump Inhibitors in Clinical Practice: A Systematic Review 63
Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia 63
Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment 61
Lipoprotein(a) and family history for cardiovascular disease in paediatric patients: A new frontier in cardiovascular risk stratification. Data from the LIPIGEN paediatric group 61
Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials 60
High-potency statins increase the risk of acute kidney injury : evidence from a large population-based study 57
Clinical Approach in the Management of Paediatric Patients with Familial Hypercholesterolemia: A National Survey Conducted by the LIPIGEN Paediatric Group 56
Refinement of pathogenicity classification of variants associated with familial hypercholesterolemia : Implications for clinical diagnosis 55
Impact of the COVID-19 Pandemic on the Therapeutic Continuity among Outpatients with Chronic Cardiovascular Therapies 52
Impact of COVID-19 Pandemic on Adherence to Chronic Therapies: A Systematic Review 52
Antibiotic Prescription in the Community-Dwelling Elderly Population in Lombardy, Italy: A Sub-Analysis of the EDU.RE.DRUG Study 52
Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia 51
Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk 50
PCSK9 inhibition in statin-intolerant HeFH patients : what's new? 49
Appropriateness of the Prescription and Use of Medicines: An Old Concept but More Relevant than Ever 46
The Role of Registers in Increasing Knowledge and Improving Management of Children and Adolescents Affected by Familial Hypercholesterolemia: the LIPIGEN Pediatric Group 46
Prescrizione dei farmaci per la terapia dell’osteoporosi nella ASL di Bergamo: anni 2006, 2007 e 2008 = Prescription of anti-osteoporosis drugs during 2006-2008 in an Italian local health unit 43
Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolemia: insights from the Italian LIPIGEN Registry 40
Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis 38
Inappropriate prescribing of drugs for peptic ulcer and gastro-esophageal reflux disease remains a matter of concern: Results from the LAPTOP-PPI cluster randomized trial 33
Operational Definitions of Polypharmacy and Their Association with All-Cause Hospitalization Risk: A Conceptual Framework Using Administrative Databases 32
A newly developed method for assessing co-exposure to free dose combinations: a proof-of-concept study using antihypertensive medications in Danish registers 30
Effect on C‐reactive protein levels of the addition of ezetimibe, bempedoic acid, or colchicine to statin treatment: A network meta‐analysis 28
Ezetimibe: Integrating Established Use with New Evidence - A Comprehensive Review 25
Genetic heterogeneity of familial hypercholesterolaemia in two populations from two different countries 23
Beta-blockers in post-acute myocardial infarction patients: Drug prescription patterns from 2018 to Italy's first wave of the COVID-19 pandemic 22
Network Analysis and Machine Learning for Signal Detection and Prioritization Using Electronic Healthcare Records and Administrative Databases: A Proof of Concept in Drug-Induced Acute Myocardial Infarction 14
Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network 1
Totale 57.139
Salva come PNG Salva come JPEG
Categoria #
all - tutte 89.367
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.367
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.637 183 194 239 257 316 227 307 291 329 357 438 499
2021/20228.938 659 686 755 760 745 620 704 1.057 961 662 668 661
2022/202310.091 594 533 605 644 690 813 970 1.128 1.094 850 1.115 1.055
2023/202415.063 1.184 1.151 1.304 1.453 1.557 1.015 1.168 1.209 1.228 1.202 1.393 1.199
2024/202515.276 1.134 1.340 1.104 1.283 1.338 1.036 1.080 1.293 1.393 1.319 1.430 1.526
2025/2026371 371 0 0 0 0 0 0 0 0 0 0 0
Totale 57.139